Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Sells $98,478.24 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson sold 13,272 shares of the company’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $7.42, for a total transaction of $98,478.24. Following the transaction, the general counsel now owns 128,473 shares of the company’s stock, valued at approximately $953,269.66. The trade was a 9.36 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Benjamin Jackson also recently made the following trade(s):

• On Monday, January 13th, Benjamin Jackson sold 7,912 shares of Sera Prognostics stock. The shares were sold at an average price of $6.38, for a total transaction of $50,478.56.
• On Monday, November 11th, Benjamin Jackson sold 4,727 shares of Sera Prognostics stock. The stock was sold at an average price of $7.32, for a total value of $34,601.64.

Sera Prognostics Trading Up 0.6 %

Shares of SERA traded up $0.04 during trading hours on Tuesday, reaching $6.37. The company had a trading volume of 134,610 shares, compared to its average volume of 143,614. Sera Prognostics, Inc. has a 12-month low of $4.98 and a 12-month high of $12.35. The firm has a 50 day simple moving average of $7.44 and a 200-day simple moving average of $7.31. The company has a market capitalization of $215.13 million, a price-to-earnings ratio of -6.43 and a beta of 0.86.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.09 million. During the same period in the previous year, the business posted ($0.23) earnings per share. Sell-side analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On Sera Prognostics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC grew its holdings in Sera Prognostics by 533.5% in the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after purchasing an additional 5,415 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Sera Prognostics in the 2nd quarter worth about $68,000. SG Americas Securities LLC purchased a new stake in shares of Sera Prognostics in the 3rd quarter worth about $78,000. Prime Capital Investment Advisors LLC purchased a new position in Sera Prognostics during the 3rd quarter valued at about $104,000. Finally, Jane Street Group LLC raised its position in Sera Prognostics by 24.8% during the third quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock worth $111,000 after acquiring an additional 2,826 shares during the last quarter. 54.64% of the stock is owned by institutional investors and hedge funds.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.